PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Spirea raises £2.4m in investment round led by Jonathan Milner and Cambridge Enterprise

Spirea Limited, a Cambridge company created to advance a new generation of antibody-drug conjugate (ADC) therapeutics, has secured funding of £2.4 million in an investment round led by Jonathan Milner and Cambridge Enterprise.

US-based R42 Group, ACF Investors, o2h Ventures, Syndicate Room and the Cambridge Angels also participated in the round.

Spirea, a spin-out from the University of Cambridge, has previously received investment from IP Group, Cambridge Enterprise, Start Codon, Jonathan Milner, o2h Ventures and Syndicate Room, and is supported by a number of successful, high-profile board members from the life sciences.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured